Krannert Institute of Cardiology, Indianapolis; Indiana Center for Vascular Biology and Medicine, Indianapolis; Indiana University School of Medicine, Indianapolis, Indianapolis; Korea University Anam Hospital, Seoul, Korea.
Catheter Cardiovasc Interv. 2014 Jan 1;83(1):E17-25. doi: 10.1002/ccd.24659. Epub 2013 Oct 7.
OBJECTIVES: To examine the comparative fate of adipose-derived stem cells (ASCs) as well as their impact on coronary microcirculation following either retrograde coronary venous (RCV) or arterial delivery. BACKGROUND: Local delivery of ASCs to the heart has been proposed as a practical approach to limiting the extent of myocardial infarction. Mouse models of mesenchymal stem cell effects on the heart have also demonstrated significant benefits from systemic (intravenous) delivery, prompting a question about the advantage of local delivery. There has been no study addressing the extent of myocardial vs. systemic disposition of ASCs in large animal models following local delivery to the myocardium. METHODS: In an initial experiment, dose-dependent effects of ASC delivery on coronary circulation in normal swine were evaluated to establish a tolerable ASC dosing range for intracoronary (IC) delivery. In a set of subsequent experiments, an anterior acute myocardial infarction (AMI) was created by balloon occlusion of the proximal left anterior descending (LAD) artery, followed by either IC or RCV infusion of 10(7) (111)Indium-labeled autologous ASCs 6 days following AMI. Indices of microcirculatory resistance (IMR) and coronary flow reserve (CFR) were measured before sacrifices to collect tissues for analysis at 1 or 24 hr after cell delivery. RESULTS: IC delivery of porcine ASCs to normal myocardium was well tolerated up to a cumulative dose of 14 × 10(6) cells (approximately 0.5 × 10(6) cells/kg). There was evidence suggesting microcirculatory trapping of ASC: at unit doses of 50 × 10(6) ASCs, IMR and CFR were found to be persistently altered in the target LAD distribution at 7 days following delivery, whereas at 10 × 10(6) ASCs, only CFR was altered. In the context of recent MI, a significantly higher percentage of ASCs was retained at 1 hr with IC delivery compared with RCV delivery (57.2 ± 12.7% vs. 17.9 ± 1.6%, P = 0.037) but this initial difference was not apparent at 24 hr (22.6 ± 5.5% vs. 18.7 ± 8.6%; P = 0.722). In both approaches, most ASC redistributed to the pulmonary circulation by 24 hr postdelivery. There were no significant differences in CFR or IMR following ASC delivery to infarcted tissue by either route. CONCLUSIONS: Selective intravascular delivery of ASC by coronary arterial and venous routes leads to similarly limited myocardial cell retention with predominant redistribution of cells to the lungs. IC arterial delivery of ASC leads to only transiently greater myocardial retention, which is accompanied by obstruction of normal regions of coronary microcirculation at higher doses. The predominant intrapulmonary localization of cells following local delivery via both methods prompts the notion that systemic delivery of ASC might provide similarly beneficial outcomes while avoiding risks of inadvertent microcirculatory compromise.
目的:研究脂肪来源的干细胞(ASCs)在逆行冠状静脉(RCV)或动脉给药后的比较命运及其对冠状动脉微循环的影响。
背景:将 ASCs 局部递送至心脏已被提议作为限制心肌梗死程度的实用方法。间充质干细胞对心脏影响的小鼠模型也显示出全身(静脉内)给药的显著益处,这促使人们对局部给药的优势产生疑问。尚无研究探讨在大动物模型中,局部递送至心肌后,ASCs 在心肌与全身之间的分布程度。
方法:在初始实验中,评估了 ASC 给药剂量对正常猪冠状动脉循环的剂量依赖性影响,以确定可接受的冠状动脉内(IC)给药 ASC 剂量范围。在一系列后续实验中,通过气囊闭塞近端左前降支(LAD)动脉创建急性前壁心肌梗死(AMI),然后在 AMI 后 6 天通过 IC 或 RCV 输注 10(7)(111)Indium 标记的自体 ASCs。在牺牲前测量微血管阻力(IMR)和冠状动脉血流储备(CFR)指数,以收集细胞给药后 1 或 24 小时的组织进行分析。
结果:IC 递送至正常心肌的猪 ASC 可耐受高达 14×10(6)个细胞的累积剂量(约 0.5×10(6)个细胞/kg)。有证据表明 ASC 存在微循环捕获:在 50×10(6)个 ASC 的单位剂量下,在给药后 7 天,在目标 LAD 分布中发现 IMR 和 CFR 持续改变,而在 10×10(6)个 ASC 时,仅 CFR 改变。在最近的 MI 背景下,与 RCV 给药相比,IC 给药时在 1 小时时保留的 ASC 百分比显著更高(57.2±12.7%比 17.9±1.6%,P=0.037),但在 24 小时时这种初始差异并不明显(22.6±5.5%比 18.7±8.6%;P=0.722)。在两种方法中,在给药后 24 小时内,大多数 ASC 重新分布到肺循环。通过两种途径将 ASC 递送至梗死组织后,CFR 或 IMR 均无显著差异。
结论:通过冠状动静脉途径选择性的血管内递送 ASC 导致类似的有限心肌细胞保留,主要将细胞重新分布到肺部。IC 动脉内递送 ASC 仅导致短暂的心肌保留增加,同时在更高剂量时伴有正常冠状动脉微循环的阻塞。通过两种方法局部递送至心脏后,细胞主要在肺内定位,这提示全身递送 ASC 可能提供类似的有益结果,同时避免无意中损害微循环的风险。
Rev Esp Cardiol (Engl Ed). 2015-11
Arq Bras Cardiol. 2011-10-7
Stem Cells Int. 2023-11-2
Nat Rev Cardiol. 2021-6
Front Cell Dev Biol. 2020-6-23
World J Stem Cells. 2019-10-26
Front Physiol. 2018-11-26
Korean Circ J. 2012-2-27
Catheter Cardiovasc Interv. 2011-1-1
Korean Circ J. 2009-3-25
Curr Opin Organ Transplant. 2010-2
Am J Physiol Heart Circ Physiol. 2009-11-25
Am J Physiol Heart Circ Physiol. 2009-9